Non-steroidal Anti-inflammatory Drugs in Tonic, Phasic and Inflammatory Mouse Models

Abstract

The principal mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of ciclooxigenases. In this study was evaluated if NSAIDs could induce antinociceptive differences according to the type of murine pain model. Male mice were injected intraperitoneally with meloxicam, diclofenac, piroxicam, metamizol, ibuprofen, naproxen and paracetamol in the writhing, tail flick and formalin orofacial tests and dose-response were analyzed to obtain the ED₅₀ of each drugs. Administration of NSAIDs produced in a dose-dependent antinociception with different potency in the tests. The relative potency of NSAIDs among the tests shows a value of 5.53 in the orofacial formalin test in phase I and 6.34 in phase II between meloxicam and paracetamol; of 7.60 in the writhing test between meloxicam and paracetamol and of 8.46 in the tail flick test between ibuprofen and paracetamol. If the comparison is made for each NSAID in the different tests, the minimum value was 0.01 for between writhing and phase II of the orofacial formalin. Meanwhile, the highest power ratio was 11.71 for diclofenac between writhing and tail flick tests. In conclusion, the results suggests that intraperitoneal NSAIDs administration induce antinociceptive activity depending on the type of pain. The results support that NSAIDs administration, induce a wide variety of antinociceptive effect, depending on the type of pain. This suggest the participation of different mechanisms of action that can be added to the simple inhibition of COXs controlled by NSAIDs.

Key words

non-steroidal anti-inflammatory drugs - writhing test - tail flick assay - formalin orofacial test

• References

• 1 Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Ann Rev Biochem 2000; 69: 1450-1820
• 2 Wong RSY. Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion. Adv Pharmacol Sci 2019; 3418975. doi:10.1155/2019/3418975
• 3 Gan TJ. Diclofenac: An update on its mechanism of action and safety profile. Curr Med Res Opin 2010; 26: 1715-1731
• 4 Dıaz-Gonzalez F, Sanchez-Madrid F. NSAIDs: Learning new tricks from old drugs. Eur. J. Immunol 2015; 45: 679-686
• 5 Gunaydin C, Sirri Bilge S. Effects of Nonsteroidal Anti-Inflammatory drugs at the molecular level. Eurasian J Med 2018; 50: 116-121
• 6 Lisowska B, Kosson D, Domaracka K. Lights and shadows of NSAIDs in bone healing: The role of prostaglandins in bone metabolism. Drug Des Devel Ther 2018; 12: 1753-1758
• 7 Pinardi G, Sierralta F, Miranda HF. Atropine reverses the antinociception of nonsteroidal anti-inflammatory drugs in the tail-flick test of mice. Pharmacol Biochem Behav 2003; 74: 603-608
• 8 Miranda HF, Puig MM, Prieto JC. et al. Synergism between paracetamol and nonsteroidal anti-inflammatoy drugs in experimental acute pain. Pain 2006; 121: 22-28
• 9 Miranda HF, Sierralta F, Prieto JC. Synergism between NSAIDs in the orofacial formalin test in mice. Pharmacol Biochem Behav 2009; 92: 314-318
• 10 Muñoz J, Navarro C, Noriega V. et al. Synergism between COX-3 inhibitors in two animal models of pain. Inflammopharmacol 2010; 18: 65-71
• 11 Miranda HF, Noriega V, Zepeda RJ. et al. Systemic synergism between codeine and morphine in three pin models in mice. Pharmacol Rep 2013; 65: 80-88
• 12 Miranda HF, Sierralta F, Aranda N. et al. Pharmacological profile of dexketoprofen in orofacial pain. Pharmacol Rep 2016; 68: 1111-1114
• 13 Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009; 2: 1-14
• 14 Isiordia-Espinoza MA, Pozos-Guillén A, Pérez-Urizar J. et al. Involvement of nitric oxide and ATP-sensitive potassium channels in the peripheral antinoceptive action of a tramadol-dexketoprofen combination in the formalin test. Drug Dev Res 2014; 75: 449-454
• 15 Miranda HF, Sierralta F, Aranda N. et al. Pharmacological profile of dexketoprofen in orofacial pain. Pharmacol Rep. 2016; 68: 1111-1114
• 16 Raffa RB, Stone Jr DJ, Tallarida RJ. Discovery of ’self-synergistic’ spinal/supraspinal antinociception produced by acetaminophen (paracetamol). J Pharmacol Exp Ther 2000; 295: 291-294
• 17 Singh N, Jabeen T, Sharma S. et al. Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: Structure of the complex formed between phospholipase A2 and diclofenac at 2.7 A resolution. Acta Crystallogr D Biol Crystallogr 2006; 62: 410-416
• 18 Wu YH, Ko TP, Guo RT. et al. Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2. Structure 2008; 16: 1714-1723
• 19 Dwivedi AK, Gurjar V, Kumar S. et al. Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs). Drug Discov Today 2015; 20: 863-873
• 20 Herrera-Garcia A, Dominguez-Luis M. Arce-Franco et al. In vivo modulation of the inflammatory response by nonsteroidal anti-inflammatory drug-related compounds that trigger L-selectin shedding. Eur J Immunol 2013; 43: 55-64
• 21 Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071
• 22 Dıaz-Gonzalez F, Sanchez-Madrid F. NSAIDs: Learning new tricks from old drugs. Eur J Immunol 2015; 45: 679-686